Amylyx Pharmaceuticals
AMLX
26.02
-0.18
-0.69%
Amylyx Pharmaceuticals
US · AMLX
#2392 by market cap
Listed 2022
26.02
-0.18
-0.69%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
Recent news
-
Rating change
Guggenheim Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $57Market Newswire · 2026/8/27
-
Rating change
H.C. Wainwright Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $55Market Newswire · 2026/8/20
-
Mizuho Securities Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Cuts Target Price to $38Market Newswire · 2026/10/29
-
Rating change
Baird Initiates Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Announces Target Price $28Market Newswire · 2026/8/7
-
Rating change
Mizuho Securities Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $30Market Newswire · 2026/8/17
-
Rating change
A Quick Look at Today's Ratings for Amylyx Pharmaceuticals(AMLX.US), With a Forecast Between $24 to $34Market Newswire · 2026/8/7
-
Rating change
Citi Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $26Market Newswire · 2026/8/4
-
Rating change
TD Cowen Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy RatingMarket Newswire · 2026/8/19
-
Rating change
Guggenheim Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $55Market Newswire · 2026/8/19
-
Rating change
LifeSci Capital Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $24Market Newswire · 2026/7/30
-
Rating change
LifeSci Capital Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $44Market Newswire · 2026/8/23
-
Earnings Flash (AMLX) Amylyx Pharmaceuticals Posts Q3 Loss $0.38 a Share, Vs. FactSet Est of $0.37 LossMT Newswires · 2026/11/5
-
H.C. Wainwright Initiates Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Announces Target Price $55Market Newswire · 2026/11/6
-
Rating change
Citi Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $26Market Newswire · 2026/8/3
-
Citi Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $39Market Newswire · 2026/11/6
-
Mizuho Securities Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $39Market Newswire · 2026/11/10
-
Rating change
Mizuho Securities Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $42Market Newswire · 2026/8/20
-
Rating change
Stifel Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Announces Target Price $45Market Newswire · 2026/10/1
-
Rating change
A Quick Look at Today's Ratings for Amylyx Pharmaceuticals(AMLX.US), With a Forecast Between $32 to $55Market Newswire · 2026/8/19
-
Rating change
Citi Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $39Market Newswire · 2026/10/15
-
Rating change
H.C. Wainwright Initiates Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Announces Target Price $34Market Newswire · 2026/7/2
-
Rating change
Analysts Offer Insights on Healthcare Companies: Amylyx Pharmaceuticals Inc (AMLX), Heart Test Laboratories, Inc. (HSCS) and Align Tech (ALGN)TipRanks · 2026/7/30
-
Citi Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $39Market Newswire · 2026/10/16
-
Rating change
Mizuho Securities Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $24Market Newswire · 2026/7/20
-
Rating change
Analysts Are Bullish on These Healthcare Stocks: Amylyx Pharmaceuticals Inc (AMLX), Guardian Pharmacy Services, Inc. Class A (GRDN)TipRanks · 2026/7/2
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 20:02:24 · For reference only, not investment advice and not tailored to your situation.
Amylyx Pharmaceuticals discussion 0 comments